Latest news

• AbbVie reports more solid data for would-be psoriasis blockbuster

  ixekizumab) and Valeant’s Siliq (brodalumab).

• Lilly claims another EU okay for Taltz

  Taltz (ixekizumab) was first approved as a treatment for psoriasis in 2016, and the new indication - which was approved in the US in December - is a boost as it plays

• Lilly mulls divestment of its animal health operations

  to surging sales of diabetes drugs Trulicity (dulaglutide) and Jardiance (empagliflozin) and a near five-fold increase for psoriasis drug Taltz (ixekizumab).

• Lilly axes 3,500 jobs in $500m-a-year cost-cutting drive

  Lilly's first-half revenues rose 8% to $5.8bn thanks to surging sales of new drugs like diabetes therapy Trulicity (dulaglutide) and psoriasis drug Taltz (ixekizumab), and the company is

• Baricitinib delay casts a pall over Lilly's results update

  Also entering a competitive sector was Lilly's new psoriasis drug Taltz (ixekizumab), which nevertheless rocketed to almost $140m in the quarter, while diabetes drug Jardiance (empagliflozin) showed signs of benefiting